Alembic Pharmaceuticals

Alembic Pharmaceuticals financials

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Stock Price

₹505.3

2023-02-17

Market Capitalization

₹99.4 B

2023-02-17

Revenue

₹52.3 B

FY, 2022

CreditSafe score

Score changed on Mar 22, 2023

Premium Content

INR	FY, 2018	FY, 2019	FY, 2020	FY, 2021	FY, 2022
Revenue	31.2B	39.3B	45.9B	52.8B	52.3B
Cost of goods sold	10.4B	11.7B	13.0B	15.0B	17.0B
Gross profit	20.9B	27.6B	33.1B	39.0B	36.0B
Gross profit margin, %	66.8%	70.4%	72.1%	73.8%	68.9%
Operating expense total	14.7B	19.0B	20.3B	24.1B	27.2B
Depreciation and amortization	1.1B	1.2B	2.1B	1.8B	2.9B
EBITDA	6.2B	8.6B	12.8B	14.9B	8.8B
EBITDA margin, %	19.7%	21.9%	27.8%	28.2%	16.9%
EBIT	5.1B	7.4B	10.1B	13.0B	6.0B
EBIT margin, %	16.3%	18.9%	22.1%	24.7%	11.4%
Interest income	6.2M	25.8M	17.3M	15.8M	17.3M
Interest expense	34.0M	184.1M	271.6M	160.2M	177.3M
Pre tax profit	5.4B	7.5B	10.0B	13.7B	6.2B
Income tax expense	1.2B	1.6B	2.0B	2.5B	1.0B
Net Income	4.2B	5.9B	8.0B	11.1B	5.2B